1. Introduction
Primary liver cancer presents high morbidity and mortality rates in China, threatening the lives and health of many people. Primary liver cancer includes three different pathological types: hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC), and mixed type (HCC-ICC). Among them, HCC accounts for 85–90% of all primary liver cancer cases [
1]. Owing to its hidden onset and lack of specific symptoms in the early stages, most patients with HCC in China are diagnosed in the middle and advanced stages and miss the opportunity for surgical curative treatment. Chemotherapies, such as transcatheter arterial chemoembolization (TACE) and hepatic arterial infusion chemotherapy, play important roles in HCC treatment; both of these use a high concentration of chemotherapeutic drugs locally administered to kill cancer cells, which also damages some normal liver cells [
2]. Of the TACE treatments, epirubicin, oxaliplatin, and fluorouracil are the most commonly used, either alone or in combination. Although the actual efficacy of TACE is relatively clear, it easily causes adverse gastrointestinal reactions, such as post-operative nausea and vomiting [
3,
4].
The gut microbiota (GM) play important roles in the occurrence, development, diagnosis, and treatment of tumors [
5]. Abuse of antibiotics, surgery, chemotherapy, environmental changes, and other factors can cause GM dysbiosis by reducing host immunity or directly damaging the intestine. Dysbiosis refers to abnormal changes in the type, quantity, and proportion of the GM that deviate from a normal physiological combination, which develop into a pathological state [
6]. GM dysbiosis leads to an imbalance in the intestinal microecosystem, characterized by a decrease in beneficial bacteria and an increase in harmful bacteria. GM dysbiosis manifests clinically as nausea, abdominal pain, diarrhea, and other symptoms [
6].
The diversity of the GM in patients with HCC after TACE treatment are reduced, evidenced by a decrease in the relative abundance of probiotics, such as Firmicutes and Bacteroidetes, and an increase in the relative abundance of pathogenic bacteria, such as Proteobacteria, Fusobacteria, and opportunistic bacteria [
7]. Simultaneously, these patients are prone to nausea, abdominal pain, diarrhea, and other gastrointestinal reactions, which may be related to an imbalance in microbiota caused by the chemotherapy drugs used in TACE treatment [
8]. In treating HCC with TACE, epirubicin, a specific anticancer drug, has similar clinical efficacy, gastrointestinal reactions, and overall survival rate to commonly used chemotherapeutic drugs, such as oxaliplatin and fluorouracil; however, the recurrence rate of epirubicin is low, tolerance is good, and drug resistance is relatively low [
9,
10].
Based on the above findings, we administered an epirubicin suspension to New Zealand white rabbits via the hepatic artery. Changes in the GM before and after chemotherapy were analyzed and compared, and the correlations among these changes, the related For this section please double check that the following details are provided for all cases: company names and addresses (city, country) of the instruments and agents, version numbers of the softwares used. For USA or Canadian companies, please provide the state name as well (i.e., city name, abbreviated state name, USA/Canada). Same for the following highlights, please confirm. inflammatory factors, and intestinal barrier proteins were explored. This study aimed to provide novel treatment insights for clinical patients with HCC and reduce adverse reactions following TACE.
2. Materials and Methods
2.1. Equipment
Sodium pentobarbital solution (3%), epirubicin suspension (10 mg in 1 mL normal saline), and raw materials were purchased from the First Hospital of Lanzhou University (Lanzhou, China). Tissue scissors, hemostatic forceps, forceps, arterial clips, suture needles, syringes, gauze, and other surgical instruments were provided by the laboratory of the First Hospital of Lanzhou University.
2.2. Animals
Male New Zealand white rabbits (2.5–3.5 kg) were purchased from the Experimental Animal Center of Lanzhou University (Lanzhou, China) and bred according to the standard conditions of the National Animal Care and Utilization Committee. The rabbits were adaptively housed for 1 week.
2.3. Operation
Thirty New Zealand white rabbits were randomly divided into the following five groups (n = 6 per group): control on post-operative day 1 (D1d), control on post-operative day 7 (D7d), chemotherapy on post-operative day 1 (T1d), chemotherapy on post-operative day 4 (T4d), and chemotherapy on post-operative day 7 (T7d). One rabbit perished in both the T1d and D7d groups during the modeling procedure. Rabbits were anesthetized using a 3% pentobarbital sodium solution (30 mg/kg) injection via the auricular vein and routinely separated using towels. The proper hepatic artery was found and separated by laparotomy, and a 1.5 mg/kg epirubicin suspension (10 mg epirubicin in 1 mL normal saline) was injected. After observing no bleeding points, the rabbits were sutured layer-by-layer, bandaged, and fixed. In the control group, the epirubicin suspension was replaced with a similar dose of normal saline, and the rest of the procedure was the same as that in the experimental group. The rabbits were anesthetized with a 3% sodium pentobarbital solution at the corresponding time points after surgery for serum, stool, and colon tissue sample collection. After sampling, the rabbits were euthanized via air embolization through the ear vein. The samples were washed with normal saline and stored at −80 °C until further analysis. The animal experimental protocol was approved by the Ethics Committee of Lanzhou University (LDYYLL2024-11).
2.4. Microbial Bioinformatics Analysis
2.4.1. Stool Sample Processing and DNA Extraction
The fecal samples collected were frozen immediately in liquid nitrogen and stored at −80 °C until analysis. Fecal genomic DNA was extracted from the fecal samples using the QIAamp® DNA Stool Mini Kit (Qiagen, Hilden, Germany), according to the manufacturer’s protocol. The concentration and purity were detected using a Nanodrop, and the integrity was assessed using regular 0.8% agarose gel electrophoresis.
2.4.2. High-Throughput Sequencing
The bacterial genomic DNA was used as the template to amplify the V3–V4 hypervariable region of the 16S rRNA gene with the forward primer (5′-CCTACGGGNGGCWGCAG-3′) and the reverse primer (5′-GACTACHVGGGTATCTAATCC-3′). Each sample was independently amplified thrice. Finally, the polymerase chain reaction (PCR) products were assessed by agarose gel electrophoresis and the PCR products from the same sample were pooled. The pooled PCR product was used as a template, and index PCR was performed using index primers to add the Illumina index to the library. The amplification products were verified by gel electrophoresis and purified using an Agencourt AMPure XP Kit (Beckman Coulter, CA, USA). The purified products were indexed to the 16S V3–V4 library. The library quality was assessed using a
[email protected] Fluorometer (Thermo Scientific, Massachusetts, MA, USA) and an Agilent Bioanalyzer 2100 system. Finally, the pooled library was sequenced on an Illumina MiSeq 250 Sequencer to generate 2 × 250 bp paired-end reads.
2.4.3. Bioinformatics Analysis
The raw reads were quality-filtered and merged using the following criteria: (1) truncation of the raw reads at any site with an average quality score < 20, removal of reads contaminated by the adapter, and further removal of reads having less than 100 bp by TrimGalore; (2) the paired-end reads were merged to tags using Fast Length Adjustment of Short reads (FLASH, v1.2.11); (3) removal of reads with ambiguous bases (N base) and reads with more than 6 bp of homopolymers by Mothur; (4) removal of reads with low complexity to obtain clean reads for further bioinformatics analysis. The remaining unique reads were chimera-checked, compared with the gold.fa database (
http://drive5.com/uchime/gold.fa), accessed on 18 October 2023, and clustered into operational taxonomic units (OTUs) using UPARSE with a 97% similarity cut-off. All OTUs were classified based on the Ribosomal Database Project (RDP) Release 9 201203 by Mothur. Rarefaction and alpha diversity (including the Shannon, Simpson, and InvSimpson indices) were analysed using Mothur. Using R project (Vegan software package, V3.3.1), the sample trees were clustered by the Bray–Curtis distance matrix, and the data were analyzed by using the unweighted pairing method of arithmetic average (UPGMAO), weighted unifrac, unweighted unifrac, Bray–Curtis, and Jaccard principal coordinate analysis (PCoA), based on OTUs. Redundancy analysis (RDA) was performed using Canoco for Windows 4.5 (Microcomputer Power, New York, NY, USA) and assessed using MCPP with 499 random permutations.
2.5. Enzyme Linked Immunosorbent Assay and D-Lactic Acid Microplate Method
Alanine aminotransferase (ALT), aspartate aminotransferase (AST), diamine oxidase (DAO), D-lactic acid (D-LA), secretory immunoglobulin A (sIgA), tumor necrosis factor-α (TNF-α), interleukin (IL)-6, IL-10, cyclooxygenase-2 (COX-2), lipopolysaccharide (LPS), Toll-like receptor 4 (TLR-4), phosphorylated signal transducer and activator of transcription 3 (pSTAT3), phosphorylated nuclear factor κb (pNF-KB), giant cell colony-stimulating factor (GM-CSF), NOD-like receptor pyrin domain-containing protein 3 (NLRP3), mucin 2 (MUC2), tight junction protein 1 (ZO-1), occludin, and claudin-1 levels were detected in serum and colon tissues and analyzed according to manufacturer’s instructions. This was performed using the following kits: rabbit ALT enzyme-linked immunosorbent assay (ELISA; ml027206, Yuanju, Shanghai, China), rabbit AST ELISA (ml036743, Yuanju, Shanghai, China), rabbit DAO ELISA (ml027888, Meilian, Shanghai, China), rabbit sIgA ELISA (ml036798, Meilian, Shanghai, China), rabbit TNF-α ELISA (ml027766, Yuanju, Shanghai, China), rabbit IL-6 ELISA kt (ml125512, Meilian, Shanghai, China), rabbit IL-10 ELISA (ml332541, Meilian, Shanghai, China), rabbit COX-2 ELISA (ml3332512, Meilian, Shanghai, China), rabbit LPS ELISA (ml44523, Meilian, Shanghai, China), rabbit TLR-4 ELISA (ml2254156, Meilian, Shanghai, China), rabbit pSTAT3 ELISA (ml1144586, Meilian, Shanghai, China), rabbit pNF-KB ELISA (ml459985, Meilian, Shanghai, China), rabbit GM-CSF ELISA (ml421125, Yuanju, Shanghai, China), rabbit NLRP3 ELISA (ml665211, Meilian, Shanghai, China), rabbit MUC2 ELISA (ml555632, Meilian, Shanghai, China), rabbit ZO-1 ELISA (ml027943, Meilian, Shanghai, China), rabbit Occludin ELISA (ml005521, Meilian, Shanghai, China), rabbit Claudin-1 ELISA (ml666985, Meilian, Shanghai, China), and D-LA content detection (ml622365, Yuanju, Shanghai, China).
2.6. Statistical Analyses
Statistical analysis was performed using SPSS 26.0 (IBM, Armonk, NY, USA) software. To determine the statistical differences between the two groups, we used an independent samples t-test and the Mann–Whitney U test. And the Spearman Rank correlation test was used for correlation analysis. The R package vegan (v2.5.6) was used for alpha diversity and species composition analysis. The R package VennDiagram (v1.6.20) was used for Venn diagram analysis; the R package ade4 (v1.7.13) was used for beta diversity NMDS analysis; the R package pheatmap (version v1.0.12) was used for environmental factor and correlation analysis. p < 0.05 was considered statistically significant (* p < 0.05, ** p < 0.01). Analysis of variance was used to analyze the differences in various indicators (p < 0.05).
4. Discussion
Changes in the GM, inflammatory factors, and intestinal barrier protein indices in New Zealand white rabbits were compared before and after injection of the chemotherapeutic drug, epirubicin, and a correlation analysis was performed. We also analyzed dynamic changes in the GM over time in the chemotherapy (experimental) group. The results showed that Firmicutes, Proteobacteria, and Bacteroidetes were the main phyla in the control and experimental groups, and that the GM diversity changed significantly after epirubicin treatment. The rabbit GM also exhibited dynamic changes at different time points following chemotherapy.
The abundance and diversity of the GM in the experimental group decreased and then increased with time after chemotherapy compared with that in the control group. The abundance of Firmicutes decreased, that of Proteobacteria increased, and that of beneficial bacteria, such as Muribaculaceae,
Enterococcus, and
Ruminococcus, decreased in the experimental group compared with that in the control group. The levels of harmful bacterial genera, such as
Bacteroides and
Escherichia shigella, also increased. In addition, with the passage of time after chemotherapy,
Ruminococcus and
E. shigella strains showed a gradual upward trend. Bacteroides, Parabacteroides, and other GM showed a gradual declining trend, whereas certain GM showed a trend of first aggravation followed by partial recovery.
Ruminococcus is a widely studied strain that converts primary bile acids to secondary ones, and its abundance is significantly decreased in patients with intestinal and liver diseases [
11,
12].
Bacteroides participate in several important metabolic activities in the human colon, including carbohydrate fermentation and nitrogen utilization, and play an important role in maintaining GM homeostasis.
Bacteroides are relatively abundant in patients with inflammatory bowel and liver diseases [
13,
14]. In this study, chemotherapy inflicted partial liver damage and intestinal inflammation. The relative abundance of
Ruminococcus decreased, that of Bacteroides increased, and that of the other GM changed significantly in the experimental group, proving that transarterial chemotherapy drug administration changes the structural composition of the GM in rabbits.
To explore the effects of changes in the GM after transarterial chemotherapy and the possible mechanism of the gut–liver axis, we analyzed serological and colonic tissue markers in rabbits. Compared with the control group, the serum ALT and AST levels in the experimental group were significantly increased, which may be related to the epirubicin-damaged liver tissue [
15]. In terms of intestinal permeability, DAO is released into the blood in response to intestinal mucosal ischemia, congestion, or injury [
16]. D-LA is mainly produced and metabolized by GM (
Streptococcus and
Enterococcus). When the intestinal barrier is intact, D-LA cannot enter the body and has no notable effects on healthy hosts. However, with GM dysbiosis and intestinal leakage, the level of D-LA increases and can enter the blood via the intestinal barrier [
17]. Therefore, DAO and D-LA are ideal indicators of the integrity and degree of damage to the intestinal mucosal mechanical barrier, which is a key link in the function of the intestinal mucosal barrier [
16,
17]. In addition, ZO-1, occludin, and claudin-1 expression levels directly reflect the intestinal mucosal barrier function [
18]. In this study, the serum and colon tissue levels of DAO, D-LA, ZO-1, and occludin were significantly higher in the experimental group than those in the control group, indicating that epirubicin disrupted intestinal barrier function and increased intestinal permeability. While chemotherapy kills tumor cells, it also increases apoptosis in normal tissues; however, these liver injuries are usually resolved in a week [
19,
20]. These findings led us to ponder whether liver function could be improved and restored in the hepatointestinal circulation after chemotherapy drugs and how it influences the state and function of the intestine.
Dynamic comparison revealed that, with the metabolism of epirubicin in the host body, the liver function recovery, intestinal barrier function improvements, and AST, DAO, and D-LA levels gradually decreased with time after chemotherapy. AST levels were close to those in the control group, and DAO and D-LA levels were still significantly higher than those in the control group. These results indicate that the recovery of intestinal barrier function occurs later than that of the liver function after chemotherapy.
LPS and TLR-4 play important roles in tumor development. Furthermore, endotoxins are important mediators of the interaction between the liver and intestines [
21]. Epirubicin entering the liver through the hepatic artery causes partial hepatocyte damage and increases intestinal permeability, which causes GM dysbiosis, which in turn induces intestinal endotoxemia and toxins are released into the liver, forming a vicious cycle [
22]. A GM imbalance stimulates the liver to transport active mediators from the biliary tract to the intestine, such as sIgA, to control the excessive growth of pathogenic bacteria and maintain intestinal homeostasis [
23]. Intestinal endotoxins, such as pathogen-associated molecular patterns, enter the liver through the portal vein system, activate TLR-4 in the liver, and produce inflammatory factors that participate in the development of various liver diseases [
23]. COX-2 is a key factor that triggers inflammatory responses. The LPS ligand of TLR-4 activates the STAT3 pathway, which activates the COX-2 signaling axis, causes local inflammation, and increases chemotherapy resistance, increasing the toxic side effects of clinical chemotherapy drugs, such as epirubicin, nausea, and diarrhea [
24]. NF-kB is also an important downstream inflammatory signal of TLR-4, which can upregulate the expression of various inflammatory cytokines, including TNF-α, IL-6, and IL-8, and downregulate the expression of anti-inflammatory factor IL-10 [
25].
Our study found that the levels of sIgA, LPS, pSTAT3, COX-2, TNF-α, IL-6, and IL-8 were significantly increased in the experimental group compared with those in the control group, while the IL-10 level was significantly decreased, and the TLR-4 and pNF-kB levels were not significantly changed. The changes in the abovementioned key signaling proteins and inflammatory factors were similar to those induced by LPS, suggesting that chemotherapy regulates LPS and TLR-4 expression via GM changes. With the gradual chemotherapy drug metabolism, these factors tend to return to normal levels. However, we can improve intestinal function by regulating the GM, improving the therapeutic effect of chemotherapy via these signaling pathways, and reducing gastrointestinal adverse reactions, such as nausea and diarrhea.
Our study has some limitations. Our sample size was small; therefore, future investigations should increase the sample size to improve data reliability. In addition, to study the effect of chemotherapeutic drugs on the host GM, we did not establish an HCC model according to the clinical state, which does not fully simulate the human disease state, making it difficult to fully represent normal GM changes. Owing to the limitations of conditions and techniques, we did not perform standard TACE in rabbits according to the clinical operation but adjusted the operation to open injection of chemotherapy drugs through the proper hepatic artery to study the effect of epirubicin on the GM. Surgical methods will inevitably have an impact on the GM and overall condition of rabbits. However, we controlled for a single variable between the control and experimental groups, namely epirubicin treatment, and maintained the same experimental procedure to reduce the influence of other factors.